| Date Filed | Type | Description |
| 02/08/2019 |
SC 13G
| DIMENSIONAL FUND ADVISORS LP reports a 7.1% stake in RAFAEL HOLDINGS INC-CLASS B |
| 01/28/2019 |
4
| ASH MENACHEM (President) has filed a Form 4 on Rafael Holdings, Inc.|
Txns:
| Granted 70,718 shares
@ $0 |
|
| 01/23/2019 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits |
| 01/18/2019 |
4
| JONAS HOWARD S (CEO) has filed a Form 4 on Rafael Holdings, Inc.|
Txns:
| Granted 1,254,200 shares
@ $6.89, valued at
$8.6M
|
|
| 01/14/2019 |
8-K
| Submission of Matters to a Vote of Security Holders |
| 01/10/2019 |
GN
| EMA Grants Orphan Drug Designation to Rafael Pharmaceuticals' devimistat (CPI-613??) for Treatment of Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) |
| 01/10/2019 |
8-K
| Other Events |
| 01/10/2019 |
GN
| EMA Grants Orphan Drug Designation to Rafael Pharmaceuticals' devimistat (CPI-613®) for Treatment of Metastatic Pancreatic Cancer |
| 01/09/2019 |
GN
| UPDATED RELEASE: Rafael Pharmaceuticals Announces Initiation of Patient Enrollment for Phase II Clinical Trial of CPI-613 for Patients with Relapsed or Refractory Burkitt Lymphoma/Leukemia |
| 01/09/2019 |
GN
| Rafael Pharmaceuticals Announces Initiation of Phase II Trial of CPI-613 in Combination with Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer |
| 01/08/2019 |
GN
| Rafael Pharmaceuticals Announces Initiation of Patient Enrollment for Phase II Clinical Trial of CPI-613 for Patients with Relapsed or Refractory Burkitt Lymphoma/Leukemia |
| 01/07/2019 |
4
| GREENBERG STEPHEN M (Director) has filed a Form 4 on Rafael Holdings, Inc.|
Txns:
| Granted 4,203 shares
@ $8.47, valued at
$35.6k
|
|
| 01/07/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/07/2019 |
4
| WEISS MICHAEL J (Director) has filed a Form 4 on Rafael Holdings, Inc.|
Txns:
| Granted 4,203 shares
@ $8.47, valued at
$35.6k
|
|
| 12/11/2018 |
GN
| Rafael Pharmaceuticals Announces Initiation of Pivotal Phase 3 Trial (AVENGER 500) of CPI-613 (devimistat) in Combination with Modified FOLFIRINOX as First Line Treatment for Patients with Metastatic Pancreatic Cancer |
| 12/10/2018 |
10-Q
| Quarterly Report for the period ended October 31, 2018 |
| 12/10/2018 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits |
| 12/06/2018 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 11/29/2018 |
GN
| Rafael Pharmaceuticals Announces Initiation of Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613 (devimistat) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) |
| 11/27/2018 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 11/21/2018 |
8-K
| Other Events |
| 11/15/2018 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 11/09/2018 |
8-K
| Other Events |
| 10/17/2018 |
10-K/A
| Annual Report for the period ended July 31, 2018 [amend] |
| 10/15/2018 |
10-K
| Annual Report for the period ended July 31, 2018 |
| 10/15/2018 |
8-K
| Quarterly results |
| 10/15/2018 |
GN
| Rafael Pharmaceuticals to Present at BIO Investor Forum 2018 |
| 09/27/2018 |
8-K
| Quarterly results |
| 09/14/2018 |
4
| JONAS HOWARD S (CEO) has filed a Form 4 on Rafael Holdings, Inc.|
Txns:
| Disposed of 787,163 shares
@ $0
Acquired 787,163 shares
@ $0
Disposed of 97,491 shares
@ $0
Acquired 97,491 shares
@ $0
Disposed of 32,711 shares
@ $0
Acquired 32,711 shares
@ $0
Disposed of 225,556 shares
@ $0
Acquired 225,556 shares
@ $0 |
|
| 09/07/2018 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits |
| 08/16/2018 |
GN
| Rafael Pharmaceuticals Receives FDA Orphan Drug Designation of CPI-613 for the Treatment of Peripheral T-Cell Lymphoma (PTCL) |
| 08/13/2018 |
GN
| Rafael Pharmaceuticals Announces Activation of Second Clinical Trial Site for the Phase I Study of CPI-613 in Patients with Relapsed or Refractory T-Cell Lymphoma |
| 07/20/2018 |
4
| ASH MENACHEM (President) has filed a Form 4 on Rafael Holdings, Inc.|
Txns:
| Paid exercise price by delivering 643 shares
@ $9.37, valued at
$6k
|
|
| 06/11/2018 |
10-Q
| Quarterly Report for the period ended April 30, 2018 |
|